MedTrace Logo

First- or Second- Class Compression Hosiery After Endovenous Laser With Sclerotherapy and Ambulatory Phlebectomy

NCT06913764 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-07-08

No results posted yet for this study

Summary

Investigators hypothesize that first class compression therapy during the postoperative period will improve patient adherence due to easier application and reduced discomfort. Therefore, planning to compare the effectiveness of fist class versus second class compression therapy two weeks after EVLA of the great saphenous vein with concomitant combined sclerotherapy and ambulatory phlebectomy of tributaries.

Conditions

  • Varicose Veins
  • Chronic Venous Disorder
  • Chronic Venous Insufficiency (CVI)
  • Venous Reflux
  • Great Saphenous Vein (GSV) With Venous Reflux Disease

Interventions

DEVICE

class I compression stockings of the RAL-GZ 387 standard: 1 month using

Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) above-knee graduated compression stockings

DEVICE

class II compression stockings of the RAL-GZ 387 standard: 1 month using

Class 2 (RAL-GZ 387 standard: 23-32 mm Hg at the ankle level) above-knee graduated compression stockings

Sponsors & Collaborators

  • Pirogov Russian National Research Medical University

    collaborator OTHER

  • Vishnevsky Center of Surgery

    collaborator OTHER

  • Moscow City Hospital named after A.K. Eramishantsev

    lead OTHER_GOV

Principal Investigators

  • Hovsep P. Manjikian, MD · Moscow City Hospital named after A.K. Eramishantsev

  • Boris Danelian, MD · Moscow City Hospital named after A.K. Eramishantsev

  • Hovsep Manjikyan, MD · Moscow City Hospital named after A.K. Eramishantsev

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-07
Primary Completion
2025-07-01
Completion
2025-07-02

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06913764 on ClinicalTrials.gov